KRYS files 8-K — Item 2.02 Results of Operations

What Was Filed

Krystal Biotech, Inc. (KRYS), a clinical-stage biotech with a $7.8 billion market capitalization, filed an 8-K (SEC accession number 000171127926000044) on May 4, 2026, at 07:07:01 ET, disclosing Item 2.02, the SEC’s defined category for results of operations and financial performance updates for a completed reporting period. This filing was submitted simultaneously with two other SEC documents: a 10-Q for the three months ended March 31, 2026, and a Schedule 13G/A amendment. Item 2.02 does not include additional regulatory items such as forward-looking guidance or corporate leadership changes, limiting the disclosure to historical financial and operational results for the first quarter of 2026. The full filing is available at https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/krys-20260504.htm.

The Disclosure

For a clinical-stage biotech like KRYS, Item 2.02 filings typically include quarterly revenue, operating expenses, net income or loss, key clinical trial milestones achieved during the period, and a summary of corporate operations aligned with the company’s lead product candidate, beremagene geperpavec (B-VEC). Per the concurrent GlobeNewswire headline referenced in public context, this filing covers KRYS’ first quarter 2026 financial results, which preliminary tracking shows missed consensus analyst estimates: EPS was not reported against a $1.45 consensus, and revenue fell short of the $112.1 million consensus estimate. Unlike prior quarterly filings, this submission does not include forward-looking statements tied to clinical trial readouts or regulatory submissions.

Cross-Reference to Prior Signals

This 8-K follows two key recent insider transaction filings: on March 6, 2026, two executive officers purchased a combined $8.3 million in KRYS common stock. EVP, Head of International Goux Laurent Louis Jean acquired 45,366 shares across multiple tranches for a total of $5,767,064, while EVP and General Counsel Thomas John Charles acquired 9,050 shares at $275.64 for $2,494,542. Additionally, as of December 31, 2025, KRYS had 343 institutional holders (a 45-quarter-over-quarter increase), with 98.2% of its float held by institutional investors, including 83 new positions and 195 increased positions. Analyst ratings have remained stable since February 2026, with 10 Buy ratings and 1 Hold rating as of April 1, 2026, unchanged from the prior two months.

What This Filing Does NOT Tell Us

First, the filing does not provide a product-by-product revenue breakdown, including sales data for B-VEC, KRYS’ lead Phase III candidate for dystrophic epidermolysis bullosa. Second, it does not include updated clinical trial timelines or topline data from ongoing studies, which are often included in Item 2.02 disclosures but not required by SEC form rules. Third, the filing does not name specific institutional investors that updated their positions in the concurrent Schedule 13G/A amendment, as publicly available 13F data only covers holdings through December 31, 2025, and does not reflect May 2026 position changes.